Clinical Trial Update: To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial to evaluate GST-HG141 in adults with chronic hepatitis B who have an inadequate response to antiviral therapy; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• GST-HG141

Snippet

Sponsor: Fujian Akeylink Biotechnology Co., Ltd. | Conditions: Chronic Hepatitis b | Phase 3 | Status: RECRUITING